Overview A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria Status: Recruiting Trial end date: 2027-08-05 Target enrollment: Participant gender: Summary The main goal of this study is to assess the safety, and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU). Phase: Phase 1/Phase 2 Details Lead Sponsor: ModernaTX, Inc.